 4 Risk factor assessment for outcomes. Risk factors at end-point in ? participants related to each outcome were determined, and therapy which was added to baseline therapy used for each disease in patients with MH was recorded at base- and end-points 3. The 6-month interval minimizes bias due to the fall or rise in the HBP or CBP measurement 10. 